ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,023Medicare Part D Prescriptions Filled, Including Refills

Rank: 538 out of 3734

$608K Total Retail Price of All Prescriptions

Rank: 462 out of 3734

157 Patients Receiving at Least One Drug in Part D
25%Patients 65 Years and Older
100% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

11% of this provider’s 157 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 2,572 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

64 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
POLYETHYLENE GLYCOL 3350 825 207 1 53
LEVOTHYROXINE SODIUM 371 52 2 2
LEVETIRACETAM 323 52 3 105
JANTOVEN 314 45 4 76
LANSOPRAZOLE 286 122 5 155
RISPERIDONE 273 47 6 62
LAMOTRIGINE 261 23 7 169
TOPIRAMATE 249 133 8 181
ATORVASTATIN CALCIUM 248 85 9 11
OLANZAPINE 244 29 10 106
IBANDRONATE SODIUM 203 46 11 235
DIVALPROEX SODIUM 198 23 12 99
RANITIDINE HCL 185 56 13 32
SERTRALINE HCL 164 26 14 18
LACTULOSE 161 11 15 137
PANTOPRAZOLE SODIUM 157 39 16 22
GLYCOPYRROLATE 153 16 17 379
IPRATROPIUM-ALBUTEROL 147 85 18 98
VALPROIC ACID 143 19 19 223
ATELVIA 132 58 20 264
TAMSULOSIN HCL 131 65 21 29
FAMOTIDINE 128 23 22 60
MIRTAZAPINE 128 25 22 45
CARBAMAZEPINE 124 0 24 172
PHENYTOIN 117 36 25 288
LITHIUM CARBONATE 112 27 26 279
CARBIDOPA-LEVODOPA 109 52 27 92
LISINOPRIL 109 25 27 3
DOXAZOSIN MESYLATE 105 32 29 100
QUETIAPINE FUMARATE 103 17 30 82
VENLAFAXINE HCL ER 95 34 31 84
CARBAMAZEPINE XR 93 24 32 336
BONIVA 88 22 33 372
LEVOCARNITINE 86 24 34 442
BACLOFEN 84 0 35 142
CLOTRIMAZOLE 83 32 36 418
METOCLOPRAMIDE HCL 80 0 37 158
ALBUTEROL SULFATE 78 32 38 128
SIMVASTATIN 77 0 39 1
NEXIUM 77 14 39 36
VIMPAT 73 12 41 352
BUDESONIDE 72 51 42 231
ZONISAMIDE 66 45 43 355
FORTEO 66 11 43 415
GABAPENTIN 66 26 43 17
HYDROCODONE-ACETAMINOPHEN 64 17 S3 46 12
TERAZOSIN HCL 61 13 47 136
DILANTIN 61 13 47 254
LOVASTATIN 59 0 49 41
ATENOLOL 53 0 50 13
ERYTHROMYCIN 52 0 51 327
TEGRETOL XR 52 26 51 447
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 5, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.